H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The offer and sale of the unregistered warrants in the concurrent private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Rule 506(b) of Regulation D promulgated thereunder and, along with the shares of Class A common stock underlying such unregistered warrants, have not been registered ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The shares of Class A common stock (or common stock equivalents) offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of Class A common stock underlying such unregistered warrants) were offered and sold by the Company pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-264142), including a base prospectus, previousl ...

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common ...

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common ...

文章核心观点 - 生物技术公司Longeveron获得FDA的快速通道认定,用于治疗轻度阿尔茨海默病的药物Lomecel-B [1][2][3] - 这将有助于加快Lomecel-B的开发和审查进程,使其能够更快地上市 [2] - Longeveron公司CEO表示,Lomecel-B在2a期临床试验中显示出整体上可以减缓/预防疾病恶化,有望成为医生和患者的重要治疗选择 [3] 公司相关 - Longeveron是一家临床阶段的生物技术公司 [1] - Longeveron公司获得FDA的快速通道认定,用于其治疗轻度阿尔茨海默病的药物Lomecel-B [1][2] - Longeveron公司CEO Wa'el Hashad对Lomecel-B获得快速通道认定表示积极评价 [3] 行业相关 - Lomecel-B有望成为治疗阿尔茨海默病的重要治疗选择 [3] - Longeveron公司将在2024年AAIC大会上分享Lomecel-B的最新临床数据 [3]

Longeveron (NASDAQ:LGVN) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company announced a new designation from the Food and Drug Administration (FDA). The FDA has granted Longeveron's Lomecel-B the Regenerative Medicine Advanced Therapy (RMAT) designation. This is the company's treatment for mild Alzheimer's Disease. This is big news for LGVN stockholders as it marks the first time the RMAT designation has been granted to a cellular therapeutic Alzheimer's treatment candidat ...

MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer's Disease. Lomecel-B™ is a proprietary, scalable, allogeneic cellular investigational therapy being ...

Longeveron previously announced top-line results for the CLEAR MIND Phase 2a clinical trial on October 5, 2023, and reported additional clinical data and imaging biomarker results on December 20, 2023. Full study results for CLEAR MIND will be reported in a Featured Research Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) on July 28, 2024. The RMAT designation is the fourth special regulatory designation received by Longeveron for Lomecel-B™. The Lomecel-B™ HLHS program ...

Neha Motwani has over 25 years of healthcare investment banking experience, most recently serving as Managing Director, Healthcare Investment Banking at William Blair. She previously held investment banking roles of increasing responsibility with Truist Securities, Oppenheimer and Company, Stifel Financial and Cowen and Company, where, collectively, she completed transactions raising approximately $7.0 billion. Ms. Motwani earned her B.A. in political science from Columbia University. Investor Contact: Dere ...

MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. Neha Motwani has over 25 years ...